Ozon Pharmaceuticals has placed 69.1 million additional shares as part of the second stage of the SPO. Of these, 65.9 million shares were repurchased with funds from the SPO and transferred to the company's founder Pavel Aleksenko in return for those sold during the SPO. Remaining 3.2 million were acquired by the company's shareholders through the exercise of a pre-emptive right. Now the total number of the company's shares is 1,168 million.